Drug Profile
Ovapuldencel-T - AiVita Biomedical
Alternative Names: AV-OVA-1; Ovarian cancer stem cell therapy - AiVita Biomedical; Ovarian cancer stem cell therapy - NeoStem OncologyLatest Information Update: 05 Jul 2023
Price :
$50
*
At a glance
- Originator Hoag Memorial Hospital Presbyterian
- Developer AiVita Biomedical; NeoStem Oncology
- Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies; Stem cell therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Most Recent Events
- 02 Jun 2023 Interim adverse events and efficacy data from a phase-II trial in Ovarian, Peritoneal and Fallopian tube cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023) (NCT02033616)
- 28 May 2021 Aivita completes enrollment in phase-II clinical trials in Ovarian, Peritoneal and Fallopian tube cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT02033616)
- 24 Sep 2020 Phase II development is ongoing for Fallopian tube cancer in USA (AIVITA Biomedical pipeline, September 2020)